Impatto dell'implementazione di Nirsevimab sulla gravità a medio termine della bronchiolite nel setting ambulatoriale: risultati dello studio prospettico OURSYN.

CONTEXT: Nirsevimab was implemented in Europe and the United States in September 2023. While its effectiveness in preventing respiratory syncytial virus (RSV)-bronchiolitis has been demonstrated by real-life studies, its impact on mid-term child health, quality of life, and parental absenteeism remains unstudied. METHODS: Infants under 1-year with a first bronchiolitis episode were recruited through the OURSYN study involving 37 primary care pediatricians in France between 2021 and 2025 (pre-nirsevimab period: 02/2021-03/2023 and nirsevimab period: 09/2023-03/2025). RSV status was determined by antigenic nasopharyngeal testing. At day 15, parents reported symptoms, quality of life (PedsQL I